{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Lymph node response rate is defined as the proportion of participants who achieve ≥ 50% decrease from baseline in the sum of the products of the greatest perpendicular diameters of index lesions. Lymph node response rate was to be assessed by an IRC.","groups":[{"description":"Idelalisib 150 mg tablet orally twice daily + rituximab 375 mg/m\\^2 intravenously starting on Day 1 for a total of 8 infusions","id":"OG000","title":"Idelalisib + Rituximab"},{"description":"Placebo tablet orally twice daily + rituximab 375 mg/m\\^2 intravenously starting on Day 1 for a total of 8 infusions","id":"OG001","title":"Placebo + Rituximab"}],"populationDescription":"Due to the early termination of the study, efficacy data were not available for all participants, and therefore the prespecified analyses were not conducted.","reportingStatus":"POSTED","title":"Lymph Node Response Rate","type":"SECONDARY"}